Precision medicine for high-risk neuroblastoma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1146817

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Despite aggressive treatment, the survival rate for high-risk neuroblastoma patients is below 50%. We recently found that these poor-outcome neuroblastomas have a defect in a key drug response pathway, called the JNK pathway. Standard-of-care neuroblastoma drugs all require the JNK pathway to kill neuroblastoma cells, although we have now identified alternative drugs that do not require JNK. We now plan to demonstrate the efficacy of these drugs in neuroblastomas with a defective JNK pathway.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $669,245.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

apoptosis | chemotherapy | neuroblastoma | signalling pathways | systems biology

Related Links